RT Journal Article
SR Electronic
T1 Will Vaccine-derived Protective Immunity Curtail COVID-19 Variants in the US?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.30.21259782
DO 10.1101/2021.06.30.21259782
A1 Mancuso, Marina
A1 Eikenberry, Steffen E.
A1 Gumel, Abba B.
YR 2021
UL http://medrxiv.org/content/early/2021/07/05/2021.06.30.21259782.abstract
AB Multiple effective vaccines are currently being deployed to combat the COVID-19 pandemic (caused by SARS-COV-2), and are viewed as the major factor in marked reductions in disease burden in regions around the world with moderate to high coverage of these vaccines. The effectiveness of COVID-19 vaccination programs is, however, significantly threatened by the emergence of new SARS-COV-2 variants that, in addition to being more transmissible and potentially more virulent than the wild (resident) strain, may at least partially evade existing vaccines. A new two-strain (one resident, the other wild) and two-group (vaccinated or otherwise) mechanistic mathematical model is designed and used to assess the impact of the vaccine-induced cross-protective efficacy on the spread the COVID-19 pandemic in the United States. Analysis of the model, which is fitted using COVID-19 mortality data for the US, shows that vaccine-induced herd immunity can be achieved if 61\% of the American population is fully vaccinated with the Pfizer or Moderna vaccines. Parameter sensitivity analysis suggests three main factors that significantly affect the COVID-19 burden in the US, namely (a) daily vaccination rate, (b) the level of cross-protection the vaccines offer against the variant, and (c) the relative infectiousness of the dominant variant relative to the wild strain. This study further suggests that a new variant can cause a significant disease surge in the US if (i) the vaccine coverage against the wild strain is low (roughly $<50\%$), (ii) the variant is much more transmissible (e.g., twice more transmissible) than the wild-type strain, or (iii) the level of cross-protection offered by the vaccine is relatively low (e.g., less than 70\%). A new variant will not cause such surge in the US if it is only moderately more transmissible (e.g., $1.56\%$ more transmissible) than the wild strain, at least 66\% of the population of the US is fully vaccinated, and the three vaccines being deployed in the US (Pfizer, Moderna, and Johnson $\&$ Johnson) offer a moderate level of cross-protection against the variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOne of the authors (ABG) acknowledge the support, in part, of the Simons Foundation (Award $\#$585022) and the National Science Foundation (Grant Number: DMS-2052363)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used for simulations are publicly available at Johns Hopkins University COVID-19 repository